Low LDN Dose Successfully Treats HIV/AIDS, Cancer and MS by Strengthening Immune System

A very low dose of the FDA-approved drug naltrexone has been discovered to be an effective up-regulator of the immune system. The new therapy, called low dose naltrexone (LDN), has shown remarkable effects on an array of illnesses including HIV/AIDS, cancer, and autoimmune diseases such as MS. The first conference concerning LDN will be held on June 11th at the New York Academy of Sciences in Manhattan. Recent clinical trials of LDN will be discussed.

New York, NY (PRWEB) April 18, 2005 -- The drug naltrexone, which in a 50 mg dose was approved by the FDA many years ago for drug abuse and for alcoholism, in less than one-tenth that dosage boosts the immune system and thus helps fight any disease that is characterized by inadequate immune function.

Investigators mounting successful clinical trials, along with physicians and patients utilizing low dose naltrexone (LDN), will make panel presentations on June 11th at a conference to be held at the New York Academy of Sciences. The keynote speaker will be Bernard Bihari, MD, a Manhattan physician and the discoverer of the clinical effects of LDN. This discovery establishes a new paradigm in medical therapy: LDN not only tends to normalize the immune system by elevating the body's endorphin levels but also accomplishes its results with virtually no side effects or toxicity.

Two pilot studies have recently been completed, one for Crohn's disease and one for multiple sclerosis (MS), and the principal investigators, respectively from Hershey Medical Center at Penn State and from Dr. Evers Clinic, a hospital for neurological disease in Germany, will be present.

The promise of LDN is significant because: (a) it can halt diseases (e.g., MS and other autoimmune diseases, HIV, and many cancers) where there are no effective treatment options; (b) it provides successful treatment while being virtually free of side effects or toxicity; and (c) were it produced in a developing country, this generic drug would offer an extremely inexpensive ($10 per year) HIV treatment, one that does not require close supervision by health professionals-the patient need only take one small capsule each night at bedtime.

The conference will be held on June 11, 2005 from 9am to 4pm at the New York Academy of Sciences, located at 2 East 63rd Street, between Fifth and Madison Avenues in Manhattan.

For additional information, comprehensive details regarding LDN are provided at http://www.ldninfo.org. The website http://www.remedyfind.com includes independent ratings of LDN by people with MS, who rank it far higher than any other MS medical treatment; and http://ldners.org/surveys.htm displays results of surveys of hundreds of people with MS, who are reporting striking reductions in disease progression as well as marked functional improvement on LDN alone.

Contact Information:
David Gluck, MD
212-734-5109
http://www.ldninfo.org

N.B.: Interested media representatives should register to attend this conference as soon as possible in order to assure a reserved seat.